wiegveld schreef op 4 februari 2021 08:26:
Komt FILGO toch nog bovendrijven?
Hoopgevend bericht
www.fiercepharma.com/pharma/abbvie-s-...But Rinvoq’s label warns of a risk of life-threatening blood clots, and one patient in the phase 3 trial in RA died of a hemorrhagic stroke. And just last week,
Pfizer disclosed data from a post-marketing trial of its competing JAK inhibitor, Xeljanz, showing an increased risk of cardiovascular events and cancer compared to TNF inhibitors.During AbbVie’s conference call, R&D chief Michael Severino, M.D., addressed the Pfizer study, emphasizing that Xeljanz’s risks don’t necessarily extend to the entire JAK class. “We are not aware of any signal of an elevated risk” for heart problems and cancer “with any JAK inhibitor, other than Xeljanz,” he said.
Of wordt dit de volgende vraag van de onderzoekers van EMA en FDA